AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Ehlers-Danlos Syndrome

Recent research efforts aimed at curing Ehlers-Danlos Syndrome.

Last updated

Ehlers-Danlos Syndrome

Overview

Ehlers-Danlos syndrome (EDS) is a group of inherited disorders that weaken connective tissue—the body’s structural material in skin, joints, blood vessels, organs, and tendons. The 2017 classification recognizes 13 EDS types; common features across types include unusually flexible or unstable joints, soft or stretchy skin, easy bruising, pain, and impaired wound healing, but the severity and affected organs differ substantially by subtype. MedlinePlus Genetics overview EDS and disability review

Prognosis is therefore highly variable: hypermobile and classic EDS often cause lifelong pain, injury, disability, and multisystem symptoms without usually shortening lifespan, whereas vascular EDS (vEDS), most often caused by harmful variants in COL3A1, can cause life-threatening arterial, intestinal, or uterine rupture. Clinical prognosis summary vEDS fibroblast study There is no cure for any EDS type. Current care focuses on prevention and symptom management: tailored strengthening and movement training, joint protection with braces or splints when appropriate, pain and fatigue management, treatment of gastrointestinal and autonomic symptoms, genetic counseling, and subtype-specific surveillance such as vascular imaging for vEDS. hEDS GeneReviews management EDS and disability review

Scope of Recent Research (2020–present)

Research activity has increased, especially around identifying the biological causes of hypermobile EDS (hEDS), mapping molecular pathways that damage the extracellular matrix (ECM; the tissue framework surrounding cells), and reducing vascular events in vEDS. EDS research priorities The field is not yet close to a body-wide curative therapy: most recent work is either mechanism discovery, animal-model testing, biomarker development, or disease-modifying risk reduction, with the strongest human trial evidence currently confined to reducing arterial complications in vEDS rather than correcting the underlying genetic disorder. ARCADE irbesartan trial EDS research priorities

Major Breakthroughs and Emerging Therapies

Vascular risk reduction with small molecules. The most clinically consequential advance has been the 2025 ARCADE randomized, double-blind trial of irbesartan—an angiotensin II receptor blocker—added to stable celiprolol treatment in adults with vEDS. Over two years, the composite outcome of vEDS-related vascular events or new/worsening arterial lesions occurred in 8 of 29 participants receiving irbesartan versus 15 of 28 receiving placebo; the reported hazard ratio was 0.42, although hypotension led to dose reduction in four participants. ARCADE irbesartan trial This is a major disease-modifying advance for vEDS risk management, but it is not a genetic cure because it does not repair COL3A1 or restore normal type III collagen throughout the body. ARCADE irbesartan trial

Hormone-pathway targeting in vEDS models. A 2026 study in a Col3a1 vEDS mouse model found that inhibiting androgen-receptor signaling removed the sex difference in survival, while a dual androgen- and mineralocorticoid-receptor antagonist gave near-complete, durable protection from vascular disease in both sexes. Selectively blocking mineralocorticoid-receptor signaling also protected mice while avoiding androgen-related sexual side effects in males. Steroid-hormone antagonism in vEDS mice This work identifies a plausible drug-repurposing route, but it remains preclinical and cannot yet establish safety or efficacy in people with vEDS. Steroid-hormone antagonism in vEDS mice

Extracellular-matrix and cell-based repair for classic EDS. In a 2024 conditional Col5a1 mouse model of classic EDS, researchers showed that disrupted collagen organization, reduced collagen deposition, inflammation, and abnormal mechanical signaling contribute to poor wound healing. Injecting healthy fibroblasts—cells that produce connective-tissue matrix—or inhibiting mechanosensitive integrin signaling improved wound closure and reduced inflammation in the mice. ECM modulation and fibroblast delivery This is an early proof of concept for localized tissue repair, not evidence that fibroblast therapy can cure classic EDS systemically. ECM modulation and fibroblast delivery

Targeting downstream collagen and matrix signaling. Molecular studies in classic EDS mice have identified altered transforming growth factor-beta signaling, lysyl oxidase, lumican, and thrombospondin-1 as potential treatment targets downstream of reduced type V collagen. Classic EDS mouse molecular study In vEDS patient fibroblasts, proteomic and gene-expression studies have likewise found abnormal ECM deposition, collagen III degradation, and increased lysyl oxidase activity, offering candidate biomarkers and targets for future medicines. vEDS fibroblast ECM study

Genetic discovery in hEDS. hEDS remains the only EDS subtype without an established diagnostic gene test, but a 2025 study of 200 people with hEDS reported enrichment of rare variants across the kallikrein gene family and identified a recurrent KLK15 variant in several families. A mouse carrying the corresponding variant developed smaller tendon collagen fibrils, cardiac-valve abnormalities, and altered immune signaling, linking matrix remodeling and immune pathways to hEDS biology. KLK15 hEDS study These findings are promising for subclassifying hEDS and eventually selecting targeted treatments, but they do not establish KLK15 as a universal hEDS cause or support clinical genetic testing or gene therapy at present. EDS research priorities KLK15 hEDS study

Clinical Trials and Experimental Approaches

The completed ARCADE trial, sponsored by Assistance Publique–Hôpitaux de Paris with support from the French Ministry of Health, tested irbesartan versus placebo for two years in adults with genetically confirmed vEDS receiving background celiprolol. Its favorable result is the most important recent controlled trial outcome in EDS, although the small sample size of 57 randomized participants means replication and longer follow-up remain important. ARCADE trial registry ARCADE irbesartan trial

Celiprolol itself remains a risk-reduction treatment rather than a cure. A 2026 Japanese retrospective cohort of 26 adults with genetically confirmed vEDS found that one patient died from hepatic-artery rupture, 11 experienced vascular events, and 14 remained event-free during follow-up; the authors concluded that nonfatal vascular complications remained frequent despite therapy. Japanese celiprolol cohort In the United States, the Phase 3 DiSCOVER study is recruiting to compare celiprolol with placebo in people with COL3A1-positive vEDS. DiSCOVER celiprolol trial

Other registered studies address symptoms or functional complications rather than cure biology. These include a planned Phase 3 trial of ultrasound-guided dextrose prolotherapy for sacroiliac and low-back pain in hEDS, estimated to begin in June 2026, and completed rehabilitation research for EDS. Dextrose prolotherapy trial Multidisciplinary rehabilitation trial Such studies may improve pain, stability, or quality of life, but they do not correct the inherited connective-tissue defect. EDS and disability review

Methodologies and Scientific Approaches

Researchers are combining patient-derived skin fibroblasts, tissue proteomics, RNA expression profiling, and measurements of collagen breakdown and cross-linking to identify disease signatures and drug targets. vEDS fibroblast ECM study These laboratory platforms are paired with genetically precise mouse models, including Col5a1 models of classic EDS and Col3a1 models of vEDS, which permit testing of wound repair, arterial rupture, drug response, and the effects of altered mechanical signaling. Classic EDS mouse molecular study Steroid-hormone antagonism in vEDS mice

For hEDS, the main methodological priority is large, carefully phenotyped genomic cohorts linked to biological samples and long-term clinical data. The HEDGE project reported analysis of 1,021 whole genomes from people meeting 2017 hEDS criteria, while parallel biomarker projects use serum proteomics and other “omics” methods to distinguish subgroups and identify actionable pathways. HEDGE and hEDS funding update EDS research priorities

Leading Institutions and Funding

Major recent contributors include Assistance Publique–Hôpitaux de Paris and the French rare-vascular-disease network, which led ARCADE; Johns Hopkins University, Howard Hughes Medical Institute, Northeastern University, and collaborating institutions behind the 2026 vEDS hormone-pathway study; UCLA and its Broad Stem Cell Research Center collaborators behind the classic EDS wound-repair model; and the Medical University of South Carolina-led international team studying KLK15 in hEDS. ARCADE irbesartan trial Steroid-hormone antagonism in vEDS mice ECM modulation and fibroblast delivery KLK15 hEDS study

The Ehlers-Danlos Society is a major patient-led research funder and infrastructure builder. Its 2023 impact report describes 1,021 HEDGE genomes from participants in 86 countries, a $240,000 serum-proteomics award to the University of Brescia’s Marco Ritelli, and a $2.375 million pledge from InVitro Cell Research for hEDS proteomics and metabolomics research. HEDGE and hEDS funding update The French Ministry of Health funded the ARCADE trial through grant PHRC 140918. ARCADE irbesartan trial

Strengths, Limitations, and Challenges

The field’s strengths are increasingly precise models, stronger international collaboration, and the first persuasive modern randomized evidence that a readily available medicine can reduce vascular events in vEDS. ARCADE irbesartan trial The vEDS pipeline also benefits from a defined causal gene, measurable arterial outcomes, and experimental models that reproduce rupture risk. Steroid-hormone antagonism in vEDS mice

The central limitations are biological diversity and scale. EDS comprises multiple disorders caused by different genes and mechanisms, while hEDS still lacks a confirmed universal molecular cause or diagnostic biomarker. EDS research priorities Individual EDS subtypes are rare, making trials small and statistically limited; variable symptoms, incomplete natural-history data, difficulty recruiting homogeneous cohorts, and weak outcome measures further slow definitive trials. EDS research priorities Whole-body gene replacement or editing would also need to safely reach a vast number of connective-tissue cells across skin, vessels, tendons, joints, and organs, so there is currently no clinical gene, RNA, or cell therapy that can be described as curative for EDS. EDS research priorities EDS and disability review

Outlook and Future Directions

As of August 8, 2026, a cure for EDS is not near-term, but the research trajectory is improving: the next milestones are confirmation and implementation studies for irbesartan plus celiprolol in vEDS, human testing of mineralocorticoid-receptor or related hormone-pathway strategies, replication of KLK15 and other hEDS genetic findings in large diverse cohorts, and validation of matrix-derived biomarkers that can divide hEDS into biologically meaningful treatment groups. ARCADE irbesartan trial Steroid-hormone antagonism in vEDS mice KLK15 hEDS study The realistic nearer-term goal is subtype-specific disease modification and prevention of major complications; a true cure will likely require a different solution for each genetic and biological form of EDS. EDS research priorities

References

Don't see your disease? Request a report